Features & Analyses

The SAIC's new Provisions emphasise the interplay between IP and competition, specifically agreements, restrictive acts, patent pools and standard essential patents. Businesses should learn from the Qualcomm and Huawei v InterDigital cases and be wary of large revenue-based penalties

Yaodong Chen, APAC director of IP for Akzo Nobel, shares with China Law & Practice his thoughts on trade secret protection in China, why inventor remuneration is burdensome for businesses and the importance of building up IP assets

The millions in fines imposed on polluters and arrests of executives indicate the seriousness of China's efforts to enforce the year-old revised Environmental Protection Law. This feature lists some of the things multinationals can do to stay out of trouble

The millions in fines imposed on polluters and arrests of executives indicate the seriousness of China's efforts to enforce the year-old revised Environmental Protection Law. This feature lists some of the things multinationals can do to stay out of trouble

Peter Fuhrman, CEO of China First Capital, explains how the country's private equity market has struggled with profit returns and the importance of diversified exit strategies. He also predicts the rise of new funds to execute high-yield deals

The Beijing IP Court's decision to reject Trunkbow's “Weixin” trademark - even though it was filed before Tencent's - has caused controversy, but one thing is clear: judges are increasingly taking into account consumers' welfare and not necessarily going by the book

The Beijing IP Court's decision to reject Trunkbow's “Weixin” trademark - even though it was filed before Tencent's - has caused controversy, but one thing is clear: judges are increasingly taking into account consumers' welfare and not necessarily going by the book

The SAIC's new guidelines make it mandatory for dominant market players to license their IP rights. Companies – high tech and pharmaceutical in particular – will need to be careful to avoid AML investigations

The SAIC's new guidelines make it mandatory for dominant market players to license their IP rights. Companies – high tech and pharmaceutical in particular – will need to be careful to avoid AML investigations